Literature DB >> 7798891

Racial differences in the seroprevalence of hepatitis A virus infection in Natal/KwaZulu, South Africa.

M A Sathar1, P N Soni, F J Fernandes-Costa, D F Wittenberg, A E Simjee.   

Abstract

The age- and race-specific seroprevalence of hepatitis A virus (HAV) infection was determined by radioimmunoassay (RIA) in 786 subjects between the ages of 6 months to 60 years. More than 50% of African children were seropositive by the age of 5 years. In blood donors (17-60 years), 50% (93/187) of Whites, 67% (110/163) of Indians, 85% (117/137) of Coloureds, and 91% (115/127) of Africans were seropositive. There was a significant difference in the seroprevalence of HAV infection between White blood donors and blood donors from the other three racial groups [Coloureds (P < 0.0001), Africans (P < 0.0001), and Indians (P < 0.001)] and between Indians and Coloureds (P < 0.0001) and Indians and Africans (P < 0.0001). There was no significance difference in HAV infection between Coloureds and Africans (P < 0.200). Eighty-seven per cent (32/37) of rural Africans had previous infection. In the African population HAV infection is acquired in childhood. There are significant racial differences in the seroprevalence of HAV infection. The surveillance of HAV infection may be used as a valuable yardstick to monitor the changing standards of hygiene and socioeconomic conditions of a community in transition in South Africa and to make rational public health decisions regarding a hepatitis A vaccination policy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7798891     DOI: 10.1002/jmv.1890440104

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  1 in total

1.  Hepatitis A virus seroprevalence in South Africa - Estimates using routine laboratory data, 2005-2015.

Authors:  Ahmad Haeri Mazanderani; Nkengafac Villyen Motaze; Kerrigan McCarthy; Melinda Suchard; Nicolette Marie du Plessis
Journal:  PLoS One       Date:  2019-06-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.